Purpose To systematically review and meta-analyze the proportion of false-positive lesions
at interim and end-of-treatment 18 F-fluoro-2-deoxy-d-glucose positron emission …

Hodgkin lymphoma is a highly curable malignancy in early and advanced stages. Most
patients are diagnosed in their teens or twenties and are expected to live decades beyond …

PURPOSE Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, and prednisone) improves overall survival (OS) in patients with …

Introduction The utility of dose escalation after positive positron emission tomography
following 2 cycles of ABVD (PET2) for Hodgkin Lymphoma (HL) remains controversial. We …

There is now good evidence that the escalated BEACOPP regimen (bleomycin, etoposide,
adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) is more effective in …

Recent results of randomized phase III studies of FDG-PET-adapted therapy for advanced
Hodgkin lymphoma (HL) have clearly demonstrated benefit to alteration of treatment …

Interim and end-of-treatment PET/CT have become central to the evaluation of Hodgkin and
non-Hodgkin lymphoma. This review article seeks to aid clinical decision making by …

Background Hodgkin's lymphoma (HL) is one of the most curable malignancies with a 5-
year survival of over 80%. Most published literature from low-middle income countries …

Assessing response to therapy in lymphoma is important for determining patients' prognosis,
guiding subsequent treatment, and may be used as an outcome measure of prognostic and …

Background The clinical impact of the positivity of the Deauville scale (DS) of positron
emission tomography (PET) performed at the end of doxorubicin, bleomycin, vinblastine and …